QUÉBEC – FEBRUARY 5, 2007 – Advitech inc. (“Advitech”) (TSX Venture: AVI) today announced the appointment of Mr. François Courteau, CA, as Vice-President and Chief Operating Officer of Advitech.
Mr. Courteau has participated to the management of many technology companies having sales and manufacturing operations, and will now bring his specific expertise to Advitech, as the Company must adapt its structure and business model to the positive evolution of DermylexTM sales and to the resulting growth of the Company. Mr. Courteau is a Chartered Accountant and has a degree in Business Administration and Industrial Relations from Laval University. Until quite recently, he was the Chief Financial Officer of Geocom TMS Inc.
”Mr. Courteau will be responsible of Advitech’s day to day operations, and will also play a major role in the preparation and planning of our growth and expansion. This will allow me to spend more time on business development and investors relations’’ explained Renaud Beauchesne, President and Chief Executive Officer. He added: ‘’we have significant milestones to achieve in 2007; these milestones are mostly related to procurement, sales organization and distribution, finance and clinical development. By adding Mr. Courteau to our existing management team, we will benefit from an additional specific expertise, and therefore increase our capacity to meet all of our milestones and objectives’’.
About Advitech Inc.
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-Mediated Inflammatory Disorders (IMID), such as psoriasis and inflammatory bowel disease. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 61,247,318. The NEW Dermylex™ website is now online at www.dermylex.ca.
Dermylex™, developed by Advitech, is an oral natural health product relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of them multi-center, double-blind and placebo-controlled, for 112 days and on 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada. For more information, please visit the www.dermylex.ca website.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.